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OBJECTIVES The purpose of this study was to evaluate whether soluble vascular cell adhesion molecule-1
(sVCAM-1) is a marker for increased cardiovascular risk.
BACKGROUND Soluble forms of cellular adhesion molecules (CAMs) may be useful markers of endothelial
activation and local or systemic inflammation. Recent studies indicate that plasma concen-
tration of soluble intercellular adhesion molecule-1 (sICAM-1) is elevated many years before
a first myocardial infarction (MI) occurs. However, only a few prospective studies have
evaluated whether sVCAM-1 is also a marker for increased cardiovascular risk.
METHODS Baseline plasma samples were obtained prospectively from 14,916 healthy participants in the
Physicians’ Health Study. In a nested, case-control study design, the plasma concentration of
sVCAM-1 was measured in 474 men with confirmed MI during the nine-year follow-up
period, and in an equal number of control subjects who remained free of reported
cardiovascular disease and who were matched for age, smoking status and length of follow-up.
RESULTS No significant difference in the median baseline sVCAM-1 concentration was found between
case and control subjects (638 vs. 634 ng/ml; p 5 NS). Cardiovascular risk was similar
between patients with sVCAM-1 levels in the highest quartile and those in the lowest
quartile, in both crude (relative risk [RR] 1.28, 95% confidence interval [CI] 0.85 to 1.92) and
adjusted (RR 1.17, 95% CI 0.71 to 1.91) matched-pairs analyses.
CONCLUSIONS In contrast to previous data on sICAM-1, we found no evidence of an association between
sVCAM-1 levels and the risk of future MI in a large cohort of apparently healthy men. These
data suggest important pathophysiologic differences between sVCAM-1 and sICAM-1 in the
genesis of atherothrombosis. (J Am Coll Cardiol 2000;36:423–6) © 2000 by the American
College of Cardiology
Leukocyte binding to cellular adhesion molecules (CAMs)
on the surface of vascular endothelial cells appears to be one
of the earliest events in the atherosclerotic process (1–4).
Increased endothelial cell expression of CAMs has been
demonstrated in response to a number of inflammatory
cytokines, including interleukin-1, interleukin-4, tumor ne-
crosis factor-alpha, interferon-gamma, lipopolysaccharide
and oxidized low density lipoprotein (LDL) (1,5–7). Patho-
logic studies have demonstrated CAMs within and adjacent
to atherosclerotic plaque (8–12), and clinical studies have
suggested a role for CAMs in plaque disruption and
subsequent acute coronary events (1,5,13,14).
After cytokine activation, CAMs are released from the
surface of endothelial cells and leukocytes, probably by
proteolytic cleavage (15,16). Plasma levels of these “shed”
CAMs can now be measured using commercially available
immunoassays (15). Although the pathogenic role of these
circulating CAMs in disease states remains unclear, these
molecules may serve as markers of endothelial activation and
local or systemic inflammation (17,18). For example, in
cross-sectional studies, the plasma concentrations of soluble
intercellular adhesion molecule-1 (sICAM-1) and soluble
vascular cell adhesion molecule-1 (sVCAM-1) correlate
with the extent of underlying atherosclerosis (19–22).
Moreover, two prospective cohort studies indicate that
baseline levels of sICAM-1 are increased many years before
a first myocardial infarction (MI) occurs (13,14). In each of
these studies, an apparent threshold effect was found, such
that increased risk was present among those with the
highest levels of sICAM-1. In one of the studies, increased
risk was observed only after two years of follow-up, sug-
gesting that an increased level of sICAM-1 is a very early
marker of risk (13).
In contrast to sICAM-1, there is a lack of prospective
data on the relation between sVCAM-1 and subsequent
coronary risk (14). We therefore sought to test this hypoth-
esis directly, using baseline plasma samples obtained from a
large cohort of apparently healthy men who were prospec-
tively observed for the occurrence of a first MI.
METHODS
We used a nested, case-control study design within the
Physicians’ Health Study (PHS)—a randomized, double-
blind, placebo-controlled trial evaluating low dose aspirin
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and beta-carotene in the primary prevention of cardiovas-
cular disease and cancer (23). Overall, the PHS consisted of
22,071 apparently healthy male physicians who were free of
a previous MI stroke, transient ischemic attack and cancer at
study entry. Before randomization, 14,916 (67.6%) men
provided a baseline plasma specimen that was collected in
EDTA and stored at 280°C until the time of assay.
Hospital records were reviewed by a blinded end points
committee for all events of incident MI reported after study
enrollment. When fatal infarction occurred, autopsy reports
and death certificates were reviewed when appropriate.
Myocardial infarction was confirmed when symptoms met
the World Health Organization criteria, in association with
either elevated cardiac enzymes or characteristic electrocar-
diographic changes.
Participants who provided a baseline plasma sample and
who had a confirmed MI during the nine-year follow-up
period were included in this study. Control subjects were
selected randomly from those study participants who pro-
vided baseline blood specimens and who remained free of
reported cardiovascular disease. Each case was matched with
one control on the basis of length of follow-up (six-month
intervals), age (within two years) and smoking status (past,
current or never). Overall, 474 pairs of MI cases and control
subjects were included in this analysis.
After thawing at room temperature, baseline plasma from
each study participant was assayed for sVCAM-1, using a
commercially available ELISA (R&D systems, Minneapo-
lis, Minnesota) (coefficient of variation 9% to 11%). Total
cholesterol, high density lipoprotein (HDL) cholesterol,
triglycerides and C-reactive protein (CRP) were also mea-
sured on baseline plasma specimens. At the time of study
entry, patients reported on age, smoking status, weight,
systolic and diastolic blood pressure, history of diabetes,
hypercholesterolemia and family history of MI.
Differences in baseline characteristics were compared
using the chi-square test for categoric variables and the
Student t test for continuous variables. Logistic regression
analyses, conditioned on the matching variables, were used
to control for potential confounding variables and random-
ized treatment assignment. Tests for trend were used to
evaluate for evidence of increased coronary risk across
increasing quartiles of sVCAM-1, with the distribution of
sVCAM-1 defined by the control group. Analyses were
performed for all patients and for the subgroup of nonsmok-
ers. Age-adjusted correlations were determined between
sVCAM-1 and total cholesterol, HDL cholesterol, triglyc-
erides and CRP. Finally, the results were stratified accord-
ing to year of follow-up to determine if the effect of
sVCAM-1 on the incidence of MI varied over time.
RESULTS
The baseline characteristics of the MI cases and control
subjects are shown in Table 1. As expected, the men with
MI had a higher prevalence of known cardiac risk factors at
baseline.
Overall, sVCAM-1 levels ranged from 55 to 2,192 ng/ml,
in a moderately rightward skewed distribution. There were
no significant differences between MI cases and control
subjects in terms of mean (669 vs. 656 ng/ml; p 5 NS) or
median (638 vs. 634 ng/ml; p 5 NS) baseline levels of
sVCAM-1.
In a crude, matched-pairs analysis, no difference in the
incidence of MI was observed between subjects with
sVCAM-1 levels in the lowest quartile and those in any of
the three higher quartiles (Table 2). In addition, we found
no evidence of an association between increasing levels of
sVCAM-1 and future coronary risk, both among all study
subjects and nonsmokers (Table 2). When adjustment was
made for body mass index, history of hypercholesterolemia,
hypertension and a family history of coronary artery disease,
there remained no association between sVCAM-1 and MI
(Table 2).
To determine whether a relation between sVCAM-1 and
MI developed with longer follow-up time, the analysis was
stratified by years of follow-up. The relative risk for MI
associated with the highest quartile of sVCAM-1 was not
statistically significant at any time during the follow-up
period (Fig. 1).
Total cholesterol was significantly correlated with
sVCAM-1, although the magnitude of the association was
small (r 5 0.09, p 5 0.02). In contrast, no significant
correlation was observed between sVCAM-1 and either
HDL cholesterol or triglyceride levels. No significant asso-
ciation was found between sVCAM-1 and CRP.
Abbreviations and Acronyms
CAM 5 cellular adhesion molecule
CRP 5 C-reactive protein
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
MI 5 myocardial infarction
PHS 5 Physicians’ Health Study
sICAM-1 5 soluble intercellular adhesion molecule-1
sVCAM-1 5 soluble vascular cell adhesion molecule-1
Table 1. Baseline Characteristics
MI Cases
(n 5 474)
Control
Subjects
(n 5 474) p Value
Age (yrs)* 58.1 57.9 —
Smoking status*
Never 44.4% 44.4% —
Past 40.8% 40.8% —
Current 14.8% 14.8% —
Body mass index (kg/m2) 25.4 25.0 0.002
Diabetes 5.1% 2.3% 0.03
Hypercholesterolemia 14.2% 10.0% 0.06
Hypertension 28.6% 17.6% 0.001
Family history of CAD 18.0% 11.7% 0.007
*Matching factor. Data are presented as the mean value or percentage of cases/
controls.
CAD 5 coronary artery disease; MI 5 myocardial infarction.
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DISCUSSION
In this prospective study, we observed no association be-
tween baseline sVCAM-1 levels and risk of future MI
among apparently healthy men. Specifically, mean and
median levels of sVCAM-1 at baseline were virtually
identical among those who subsequently had an MI and
those who remained free of cardiovascular disease. More-
over, no evidence of an association was observed even
among those with the very highest baseline levels.
Differences between sVCAM-1 and sICAM-1. The cur-
rent results for sVCAM-1 are clearly distinct from those
results previously reported in this cohort for sICAM-1 (13).
In our previous study, we found that elevated baseline
concentrations of sICAM-1 were independently associated
with an increased risk of MI, and that this risk increased
over time. Furthermore, concentrations of sICAM-1 were
strongly associated with concentrations of CRP, a marker of
systemic inflammation that has been shown to be an
independent risk factor for adverse cardiovascular events in
this and other cohorts (24–27). In contrast, our current null
data for sVCAM-1 are consistent with prospective data
derived from the Atherosclerosis Risk In Communities
(ARIC) study (14). In that analysis, as in the PHS,
sICAM-1 but not sVCAM-1 was significantly associated
with future MI. The consistency of these two large, pro-
spective studies suggests that important pathophysiologic
differences exist between VCAM-1 and ICAM-1 in the
genesis of atherothrombosis.
Vascular cell adhesion molecule-1 is a member of the
immunoglobulin superfamily and the receptor for the ligand
very late antigen-4, a beta1 integrin found only on the
surface of mononuclear cells (5). In a rabbit model of
atherogenesis, VCAM-1 was highly expressed on endothe-
lial cells at very early stages of atherogenesis (2–4). His-
topathologic studies in humans, however, have generally not
found high level VCAM-1 expression (8), except in areas of
intimal neovascularization (9). These studies have shown
clear differences between VCAM-1 and ICAM-1 expres-
sion in normal and atherosclerotic arteries. Although
VCAM-1 is not expressed on normal endothelium,
ICAM-1 is constitutively expressed at low levels (8,11,28).
In human atheroma, ICAM-1 is highly expressed by both
endothelial cells and subendothelial macrophages. In con-
trast, VCAM-1 is found in fewer than one-third of lesions,
with expression predominantly restricted to endothelial cells
and occasional spindle-shaped cells (8). The number of cells
within the atheroma expressing VCAM-1 is therefore
markedly less than the number expressing ICAM-1.
Other indirect lines of evidence point toward an associ-
ation between atherosclerosis and sICAM-1, but not
sVCAM-1. Although smoking is clearly associated with
increased sICAM-1 levels (13,29), we did not find an
association between smoking and sVCAM-1 levels. Simi-
larly, although increased sICAM-1 is also associated with
elevated levels of CRP (25), we found no association
between VCAM-1 and this sensitive inflammatory marker.
Potential study limitations. The design of our study
prevents direct assessment of the role of membrane-bound
VCAM-1 in coronary atherosclerosis. It is possible that in
contrast to ICAM-1, levels of soluble VCAM-1 do not
reflect expression of membrane-bound VCAM-1. Indeed,
some evidence exists that the “shedding” process may be
different for different CAMs. For example, Pigott et al. (16)
Figure 1. Relative risk (95% confidence interval) for first MI associated
with a baseline sVCAM-1 concentration $ the 75th percentile, according
to year of follow-up.
Table 2. Crude and Adjusted Relative Risks of First Myocardial Infarction, According to Baseline Concentration of Soluble Vascular
Cell Adhesion Molecule-1
Quartile 1
(<525 ng/ml)
Quartile 2
(525–634 ng/ml)
Quartile 3
(634–748 ng/ml)
Quartile 4
(>748 ng/ml) p Trend
Crude analysis (all patients)
RR (95% CI) 1.0 1.16 (0.79–1.69) 1.07 (0.72–1.60) 1.28 (0.85–1.92) 0.30
p Value 0.44 0.75 0.23
Crude analysis (nonsmokers)
RR (95% CI) 1.0 1.02 (0.68–1.55) 0.96 (0.62–1.50) 1.18 (0.76–1.83) 0.48
p Value 0.91 0.87 0.45
Adjusted analysis (all patients)
RR (95% CI) 1.0 1.00 (0.63–1.59) 1.06 (0.66–1.73) 1.17 (0.71–1.91) 0.48
p Value 1.0 0.80 0.54
Adjusted analysis (nonsmokers)
RR (95% CI) 1.0 0.78 (0.46–1.31) 0.82 (0.47–1.43) 0.96 (0.55–1.66) 0.87
p Value 0.35 0.49 0.88
CI 5 confidence interval; RR 5 relative risk.
425JACC Vol. 36, No. 2, 2000 de Lemos et al.
August 2000:423–6 Soluble Vascular Cell Adhesion Molecule-1 and MI
found a greater proportion of soluble to membrane-bound
VCAM-1 than ICAM-1 (16), suggesting that VCAM-1
may be cleaved from the cell surface more readily than
ICAM-1.
A second potential limitation is our use of frozen plasma
samples for analysis. The distribution of baseline sVCAM-1
values in the current study is within the expected range for
this assay (6 1 SD range 395 to 714 ng/ml), however,
suggesting that the frozen specimens were suitable samples
for analysis. As with any null study, consideration must be
given to the possibility that the study was not sufficiently
powered to detect small differences in risk. The current
study, however, had .80% power to detect a relative risk as
low as 2.0. Finally, although we found no association
between sVCAM-1 and cardiovascular events through eight
years of follow-up, it is possible that even longer follow-up
would be necessary to detect such an association. This is at
least theoretically plausible in light of the proposed role for
sVCAM-1 very early in the atherosclerotic process (2–4).
Conclusions. The plasma concentration of sVCAM-1
does not appear to be a marker for future MI among
apparently healthy men. When interpreted with our
ICAM-1 results, these data strongly suggest that there are
important distinctions between different sCAMs in the
genesis of atherothrombosis. Future studies, both at the
basic and clinical level, should focus on the mechanisms and
implications of these differences.
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